Analyst Price Target is $225.00
▲ +1,826.37% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Galecto in the last 3 months. The average price target is $225.00, with a high forecast of $225.00 and a low forecast of $225.00. The average price target represents a 1,826.37% upside from the last price of $11.68.
Current Consensus is
Buy
The current consensus among 1 polled investment analysts is to buy stock in Galecto. This rating changed within the last month from a Moderate Buy consensus rating.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.
Read More